Stempeutics gets EMA approval to market stem cell drug in EU – Economic Times
|
Stempeutics gets EMA approval to market stem cell drug in EU
Economic Times NEW DELHI: Drug major Cipla today said its joint venture firm Stempeutics Research has received approval from the European Medicines Agency (EMA) for its stem–cell based drug Stempeucel, which is used to treat Thromboangiitis Obliterans (TAO). Stempeutics receives ATMP classification from EMA for its novel stem cell drug … Stempeutics Receives Advanced Therapy Medicinal Product (ATMP … |
